# US 2025/0152670 A1 · Method for alleviating pulmonary fibrosis using epidermal growth factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152670 A1
- Document ID: US20250152670A1
- Status: Published application
- Kind: A1
- Application number: 18/839,688
- Filed: 2022-04-28
- Published: 2025-05-15
- Earliest claimed: 2022-04-28
- Assignees: Wenzhou Prarucom Bio-Chemical Technology Co.; Puhsin Ltd.
- Applicants: Wenzhou Prarucom Bio-Chemical Technology Co.; Puhsin Ltd.
- Inventors: Le-Shin CHANG; Shang-Yu CHIA
- Web page: https://patentgrep.com/patent/US20250152670A1

## CPC

- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 31/722: Chitin, chitosan
- A61K 31/728: Hyaluronic acid
- A61K 38/014: {from connective tissue peptides, e.g. gelatin, collagen}
- A61P 11/00: Drugs for disorders of the respiratory system
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

A method for alleviating pulmonary fibrosis includes administering to a subject in need thereof a composition containing epidermal growth factor. The composition further contains a polysaccharide and hyaluronic acid. Epidermal growth factor, the polysaccharide, and hyaluronic acid are present in a weight ratio ranging from 1:0.5:12.5 to 1:250:1250. Epidermal growth factor can exhibit satisfactory efficacy in alleviating pulmonary fibrosis and PF-related tissue lesions, and this efficacy can be enhanced when epidermal growth factor is used in combination with the polysaccharide and hyaluronic acid.

## Claims

### Claim 1

A method for alleviating pulmonary fibrosis, comprising administering to a subject in need thereof a composition containing epidermal growth factor.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the composition further contains a polysaccharide and hyaluronic acid.

### Claim 3 (depends on 2)

The method as claimed in claim 2, wherein epidermal growth factor, the polysaccharide, and hyaluronic acid are present in a weight ratio ranging from 1:0.5:12.5 to 1:250:1250.

### Claim 4 (depends on 3)

The method as claimed in claim 3, wherein epidermal growth factor, the polysaccharide, and hyaluronic acid are present in a weight ratio of 1:5:125.

### Claim 5 (depends on 2)

The method as claimed in claim 2, wherein the polysaccharide is selected from the group consisting of chitosan, chitin, glycosaminoglycan, cellulose, starch, peptidoglycan, and combinations thereof.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the polysaccharide is chitosan.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the composition is formulated as a food product.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein the composition is formulated as a pharmaceutical composition.

### Claim 9 (depends on 8)

The method as claimed in claim 8, wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a parenteral dosage form, an oral dosage form, a topical dosage form, and an inhalation dosage form.

### Claim at position 10

10-25. (canceled)
